PAI-1 Production by Reactive Astrocytes Drives Tissue Dysfibrinolysis in Multiple Sclerosis Models

Overview

Journal Cell Mol Life Sci

Publisher Springer

Specialty Biology

Date 2022 May 28

PMID 35633384

Authors

Heloise Lebas

Sylvaine Guerit

Audrey Picot

Anne Cecile Boulay

Antoine Fournier

Denis Vivien

Martine Cohen Salmon

Fabian Docagne

Isabelle Bardou

Affiliations

Soon will be listed here.

Abstract

Background: In multiple sclerosis (MS), disturbance of the plasminogen activation system (PAS) and blood brain barrier (BBB) disruption are physiopathological processes that might lead to an abnormal fibrin(ogen) extravasation into the parenchyma. Fibrin(ogen) deposits, usually degraded by the PAS, promote an autoimmune response and subsequent demyelination. However, the PAS disruption is not well understood and not fully characterized in this disorder.

Methods: Here, we characterized the expression of PAS actors during different stages of two mouse models of MS (experimental autoimmune encephalomyelitis-EAE), in the central nervous system (CNS) by quantitative RT-PCR, immunohistofluorescence and fluorescent in situ hybridization (FISH). Thanks to constitutive PAI-1 knockout mice (PAI-1 KO) and an immunotherapy using a blocking PAI-1 antibody, we evaluated the role of PAI-1 in EAE models and its impact on physiopathological processes such as fibrin(ogen) deposits, lymphocyte infiltration and demyelination.

Results: We report a striking overexpression of PAI-1 in reactive astrocytes during symptomatic phases, in two EAE mouse models of MS. This increase is concomitant with lymphocyte infiltration and fibrin(ogen) deposits in CNS parenchyma. By genetic invalidation of PAI-1 in mice and immunotherapy using a blocking PAI-1 antibody, we demonstrate that abolition of PAI-1 reduces the severity of EAE and occurrence of relapses in two EAE models. These benefits are correlated with a decrease in fibrin(ogen) deposits, infiltration of T4 lymphocytes, reactive astrogliosis, demyelination and axonal damage.

Conclusion: These results demonstrate that a deleterious overexpression of PAI-1 by reactive astrocytes leads to intra-parenchymal dysfibrinolysis in MS models and anti-PAI-1 strategies could be a new therapeutic perspective for MS.

Citing Articles

Proteomic analysis reveals candidate molecules to mediate cortical pathology and identify possible biomarkers in an animal model of multiple sclerosis.

Silva B, Leal M, Farias M, Nava A, Galvan D, Fernandez E Front Immunol. 2025; 16:1505459.

PMID: 40018028 PMC: 11864942. DOI: 10.3389/fimmu.2025.1505459.

Mechanisms behind elevated serum levels of plasminogen activator inhibitor-1 in frontotemporal lobar degeneration.

Angelucci F, Hort J Neural Regen Res. 2024; 20(8):2317-2318.

PMID: 39359087 PMC: 11759028. DOI: 10.4103/NRR.NRR-D-24-00335.

A deep phenotyping study in mouse and iPSC models to understand the role of oligodendroglia in optic neuropathy in Wolfram syndrome.

Ahuja K, Vandenabeele M, Nami F, Lefevere E, Van Hoecke J, Bergmans S Acta Neuropathol Commun. 2024; 12(1):140.

PMID: 39198924 PMC: 11351506. DOI: 10.1186/s40478-024-01851-7.

References

Baumeier C, Escher F, Aleshcheva G, Pietsch H, Schultheiss H . Plasminogen activator inhibitor-1 reduces cardiac fibrosis and promotes M2 macrophage polarization in inflammatory cardiomyopathy. Basic Res Cardiol. 2021; 116(1):1. PMC: 7801308. DOI: 10.1007/s00395-020-00840-w. View

Van De Craen B, Scroyen I, Abdelnabi R, Brouwers E, Lijnen H, Declerck P . Characterization of a panel of monoclonal antibodies toward mouse PAI-1 that exert a significant profibrinolytic effect in vivo. Thromb Res. 2011; 128(1):68-76. DOI: 10.1016/j.thromres.2011.01.011. View

East E, Baker D, Pryce G, Lijnen H, Cuzner M, Gveric D . A role for the plasminogen activator system in inflammation and neurodegeneration in the central nervous system during experimental allergic encephalomyelitis. Am J Pathol. 2005; 167(2):545-54. PMC: 1603566. DOI: 10.1016/S0002-9440(10)62996-3. View

Liddelow S, Barres B . Reactive Astrocytes: Production, Function, and Therapeutic Potential. Immunity. 2017; 46(6):957-967. DOI: 10.1016/j.immuni.2017.06.006. View

Bruckert G, Vivien D, Docagne F, Roussel B . Normalization of Reverse Transcription Quantitative PCR Data During Ageing in Distinct Cerebral Structures. Mol Neurobiol. 2015; 53(3):1540-1550. PMC: 5639144. DOI: 10.1007/s12035-015-9114-5. View

Petersen M, Ryu J, Akassoglou K . Fibrinogen in neurological diseases: mechanisms, imaging and therapeutics. Nat Rev Neurosci. 2018; 19(5):283-301. PMC: 6743980. DOI: 10.1038/nrn.2018.13. View

Lundgaard I, Osorio M, Kress B, Sanggaard S, Nedergaard M . White matter astrocytes in health and disease. Neuroscience. 2013; 276:161-73. PMC: 4016995. DOI: 10.1016/j.neuroscience.2013.10.050. View

Docagne F, Nicole O, Marti H, MacKenzie E, Buisson A, Vivien D . Transforming growth factor-beta1 as a regulator of the serpins/t-PA axis in cerebral ischemia. FASEB J. 1999; 13(11):1315-24. DOI: 10.1096/fasebj.13.11.1315. View

Onodera H, Nakashima I, Fujihara K, Nagata T, Itoyama Y . Elevated plasma level of plasminogen activator inhibitor-1 (PAI-1) in patients with relapsing-remitting multiple sclerosis. Tohoku J Exp Med. 2000; 189(4):259-65. DOI: 10.1620/tjem.189.259. View

10.

Poggi M, Paulmyer-Lacroix O, Verdier M, Peiretti F, Bastelica D, Boucraut J . Chronic plasminogen activator inhibitor-1 (PAI-1) overexpression dampens CD25+ lymphocyte recruitment after lipopolysaccharide endotoxemia in mouse lung. J Thromb Haemost. 2007; 5(12):2467-75. DOI: 10.1111/j.1538-7836.2007.02757.x. View

11.

Ryu J, Rafalski V, Meyer-Franke A, Adams R, Poda S, Rios Coronado P . Fibrin-targeting immunotherapy protects against neuroinflammation and neurodegeneration. Nat Immunol. 2018; 19(11):1212-1223. PMC: 6317891. DOI: 10.1038/s41590-018-0232-x. View

12.

Fernandez-Monreal M, Lopez-Atalaya J, Benchenane K, Leveille F, Cacquevel M, Plawinski L . Is tissue-type plasminogen activator a neuromodulator?. Mol Cell Neurosci. 2004; 25(4):594-601. DOI: 10.1016/j.mcn.2003.11.002. View

13.

Thapa B, Kim Y, Kwon H, Kim D . The LRP1-independent mechanism of PAI-1-induced migration in CpG-ODN activated macrophages. Int J Biochem Cell Biol. 2014; 49:17-25. DOI: 10.1016/j.biocel.2014.01.008. View

14.

Ryu J, Petersen M, Murray S, Baeten K, Meyer-Franke A, Chan J . Blood coagulation protein fibrinogen promotes autoimmunity and demyelination via chemokine release and antigen presentation. Nat Commun. 2015; 6:8164. PMC: 4579523. DOI: 10.1038/ncomms9164. View

15.

Itoh N, Itoh Y, Tassoni A, Ren E, Kaito M, Ohno A . Cell-specific and region-specific transcriptomics in the multiple sclerosis model: Focus on astrocytes. Proc Natl Acad Sci U S A. 2017; 115(2):E302-E309. PMC: 5777065. DOI: 10.1073/pnas.1716032115. View

16.

Fournier A, Gauberti M, Quenault A, Vivien D, Macrez R, Docagne F . Reduced spinal cord parenchymal cerebrospinal fluid circulation in experimental autoimmune encephalomyelitis. J Cereb Blood Flow Metab. 2018; 39(7):1258-1265. PMC: 6668509. DOI: 10.1177/0271678X18754732. View

17.

Kroksveen A, Opsahl J, Guldbrandsen A, Myhr K, Oveland E, Torkildsen O . Cerebrospinal fluid proteomics in multiple sclerosis. Biochim Biophys Acta. 2014; 1854(7):746-56. DOI: 10.1016/j.bbapap.2014.12.013. View

18.

Louessard M, Lacroix A, Martineau M, Mondielli G, Montagne A, Lesept F . Tissue Plasminogen Activator Expression Is Restricted to Subsets of Excitatory Pyramidal Glutamatergic Neurons. Mol Neurobiol. 2015; 53(7):5000-12. DOI: 10.1007/s12035-015-9432-7. View

19.

Hultman K, Blomstrand F, Nilsson M, Wilhelmsson U, Malmgren K, Pekny M . Expression of plasminogen activator inhibitor-1 and protease nexin-1 in human astrocytes: Response to injury-related factors. J Neurosci Res. 2010; 88(11):2441-9. DOI: 10.1002/jnr.22412. View

20.

Perez-Martin M, Gonzalez-Platas M, Jimenez-Sosa A, Plata-Bello J, Carrillo-Padilla F, Franco-Maside A . Can fibrinolytic system components explain cognitive impairment in multiple sclerosis?. J Neurol Sci. 2017; 382:66-72. DOI: 10.1016/j.jns.2017.09.034. View